Low dose doxorubicin

DRUG2 trials

Sponsors

The Netherlands Cancer Institute

Conditions

Breast CancerMetastatic Breast Cancer

Phase 2

Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients

The Netherlands Cancer InstituteBreast Cancer

Start: 2015-08-31End: 2025-08-31Target: 84Updated: 2022-03-22

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

RecruitingNCT04159818

The Netherlands Cancer InstituteMetastatic Breast Cancer

Start: 2020-02-21End: 2026-12-15Target: 52Updated: 2022-03-22

Related Papers

Abstract 3443: Tumor and microenvironmental co-evolution in metastatic triple-negative breast cancer during immunotherapy

Cancer Research2026-04-03

CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.

2025-12-01

Abstract PS17-09: Immune landscape and clinical features of acquired resistance to immune checkpoint blockade in triple negative breast cancer

Clinical Cancer Research2025-06-13

Abstract P1-07-30: Phase II adaptive TONIC2 trial to dissect immunomodulatory capacity of doxorubicin or cisplatin induction followed by anti-PD1 in mTNBC

Clinical Cancer Research2025-06-13

Abstract 3894: The temporal influence of the tumor microenvironment in response to checkpoint blockade

Cancer Research2024-03-221 citations

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

2020-05-1214 citations

Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.

Journal of Clinical Oncology2018-05-2040 citations